Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) provided program updates on TNX-4800, a long-acting human monoclonal antibody designed for seasonal prophylaxis against Lyme disease. The company noted that there are currently no FDA-approved vaccines or prophylactics for Lyme disease, highlighting the potential significance of this candidate. TNX-4800 targets the outer surface protein A of Borrelia burgdorferi, the bacterium that causes Lyme disease, and is being developed as a once-yearly subcutaneous administration intended to provide protection throughout the U.S. tick season.
Tonix plans to meet with the FDA in 2026 to discuss Phase 2/3 development options, including the potential use of a controlled human infection model. The company expects to have GMP-manufactured investigational product available for testing in early 2027. This timeline suggests a strategic approach to accelerate development by leveraging modern clinical trial designs.
The update underscores the importance of Tonix's infectious disease portfolio, which also includes TNX-801, a vaccine in development for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent supported by a U.S. Department of Defense contract worth up to $34 million over five years. For more details, the full press release is available at https://ibn.fm/Wt9Ek.
Tonix is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. The company markets FDA-approved TONMYA™, a first-in-class, non-opioid analgesic for fibromyalgia, and two treatments for acute migraine: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray). The development portfolio focuses on central nervous system disorders, immunology, immuno-oncology, rare disease, and infectious disease.
The advance of TNX-4800 addresses a significant public health need. Lyme disease is the most common vector-borne disease in the United States, with hundreds of thousands of cases reported annually. A seasonal prophylactic could reduce the burden of disease and the risk of long-term complications such as arthritis and neurological issues. The absence of FDA-approved options makes TNX-4800 a potentially important addition to preventive medicine.
Tonix operates a state-of-the-art infectious disease research facility in Frederick, Md., supporting its development programs. The company's progress with TNX-4800 will be closely watched by investors and public health officials alike. For ongoing updates, visit the company's newsroom at https://ibn.fm/TNXP.
